10 OCT 1990
Common side-effects (which can last up to 24 hours after discontinuation) include
dry mouth, blurred vision (usually near vision), pupil paralysis (light sensitivity),
and drowsiness. Uncommon but potentially severe side-effects include
disorientation, hallucinations, and urinary retention.
Precautions: The medication should not be given to anyone with a history of
glaucoma or urinary tract obstruction symptoms. Concurrent use of injectable
antimotion sickness medications with transcutaneous scopolamine may increase
risk of adverse reaction.
This medication should be prescribed initially by a medical officer, if available. It
should be used only after other methods of motion sickness control have proven
unsatisfactory. When prescribed, the health record entry will reflect that no
contraindications to use exist, potential adverse reactions have been discussed, and
other methods were not satisfactory. On refill or renewal the provider must
document that there have been no significant side effects.
Aviation personnel are not allowed to use scopolamine and remain in flying status.
Aviation personnel using scopolamine will be grounded for an additional 24 hours
after its use is discontinued.
Personnel in direct control of vessels or SAR boats, e.g., SAR boat coxswains,
officer-of-the-day, helmsmen, lookouts, etc., may use scopolamine only after a 36-
hour trial of use during which they experience no significant side-effects which
would tend to make them unsafe as bridge watchstanders. The result of this trial
should be documented in the health record by a medical officer, health services
technician, or commanding officer.
Federal Supply System information:
Scopolamine patches, 1.5 mg
U/I: PG (12 patches)
Duration of Treatment. Antimotion sickness medication is intended only to help
personnel adapt to their moving environment and get their "sea legs." It is not intended to
be used for longer than 10 to 15 days at a time. Personnel that require continuous
medication or have symptoms poorly controlled should be evaluated for chronic motion